Precision Medicine Reshapes Brain Tumour Care: Survival Improves as Molecular Diagnostics and Targeted Therapies Advance
核心洞察
Median survival in high-grade glioma (搜索) has improved from 9–12 months to 14–18 months, with nearly 40% of Grade-III and Grade-IV patients surviving beyond two years at some centers.
Molecular markers such as IDH1 (搜索) mutations and MGMT (搜索) status are guiding targeted therapies like Vorasidenib, moving treatment away from a one-size-fits-all approach.
Technologies including neuronavigation, fluorescent markers, and stereotactic radiosurgery are enabling more precise tumour removal while preserving healthy tissue.
For decades, a diagnosis of high-grade glioma (搜索) carried a grim prognosis with limited therapeutic options. Today, advances in molecular diagnostics, precision surgery, targeted therapies, and modern radiation techniques are steadily reshaping that outlook. According to neuro-oncology experts, median survival among many high-grade glioma patients has improved from approximately 9–12 months to 14–18 months, while some centers are reporting nearly 40% two-year survival among Grade-III and Grade-IV glioma patients. A small subset of patients are now surviving beyond a decade.
Dr Shyam Agarwal, senior consultant in medical oncology at Sir Ganga Ram Hospital, emphasized that the perception of brain tumours as invariably fatal is outdated. "Once people hear the word tumour in the brain, many feel nothing can be done and life has come to an end. But brain tumours can be benign or malignant, and even among malignant tumours there are different grades. Today, we have multiple treatment options, including surgery, radiation and targeted drugs, which can control disease for long periods and, in selected cases, even offer a cure," he said.
Surgical Precision and Radiation Advances
Improvements in surgical technology have been central to better outcomes. Dr Amitabh Gupta, director of neurosurgery at PSRI Hospital (搜索), noted that tools such as neuronavigation, operating microscopes, and fluorescent markers now allow surgeons to distinguish tumour tissue more accurately during surgery. "These tools help maximise safe tumour removal while preserving healthy nervous tissue. Combined with stereotactic radiosurgery and molecularly guided chemotherapy, they are improving tumour control, survival and quality of life. Even in recurrent tumours, repeat surgery along with chemo-radiosurgery is yielding encouraging results," he said.
On the radiation oncology front, Dr Tejinder Kataria, chairperson of radiation oncology at Medanta (搜索), highlighted how advances in radiation delivery have transformed care. "We are now able to deliver highly precise tumoricidal doses while protecting normal tissue. Median survival has improved from around 9–12 months to 14–18 months. Nearly 40% of our Grade-III and -IV glioma (搜索) patients survive beyond two years, and some have lived for over a decade," she said.
Molecular Diagnostics Drive Targeted Treatment
Molecular testing has become central to treatment planning. Dr Agarwal explained that comprehensive genomic profiling is increasingly essential. "If an IDH1 (搜索) mutation is identified, patients may benefit from targeted therapies such as Vorasidenib. Gene sequencing is helping doctors identify precision-medicine options that were not available a few years ago," he said.
Dr R Ranga Rao, chairman of medical oncology at Paras Health (搜索), reinforced this view: "Markers such as IDH mutations and MGMT (搜索) status, along with comprehensive genomic sequencing, are helping identify patients who may benefit from targeted therapies. Precision diagnostics and multidisciplinary care are translating into longer survival and better quality of life."
The Chronic Care Challenge
Ahead of World Brain Tumour Day on June 8, specialists are also urging stronger support systems as brain tumour care increasingly resembles long-term chronic disease management. Bhopal-based neurosurgeon Dr Nitin Garg stressed that malignant gliomas often require repeated cycles of surgery, radiation, chemotherapy, and imaging. He noted that treatment costs in cities such as Bhopal average Rs 5–6 lakh, excluding follow-up expenses, with families facing hidden burdens including extended travel, prolonged hospital stays, and loss of income as caregivers leave jobs.
Under Ayushman Bharat PM-JAY, most brain tumours are covered, offering crucial financial relief. However, Dr Bharat Bhosale highlighted that while modern neuro-oncology integrates advanced diagnostics and targeted treatments, affordability remains a barrier to widespread access to genomic profiling and precision medicine.
Persistent Challenges and Future Directions
Despite these advances, delayed diagnosis remains a major challenge. Dr Agarwal noted that symptoms such as persistent headaches are often treated as stress, migraine, or other common conditions, delaying diagnosis and treatment. Specialists are also reporting a growing number of younger adults presenting with gliomas and astrocytomas.
Brain tumours account for approximately 2% of all cancers diagnosed in India, while gliomas and astrocytomas occur at an estimated rate of five to 10 cases per 100,000 population annually. Looking ahead, researchers believe the future lies in precision oncology and next-generation immunotherapies. Dr Pranav Sopory, medical and patient affairs director at Servier India (搜索), said treatment is moving away from a "one-size-fits-all" approach. "Innovations such as targeted therapies, immunotherapy and CAR-T cell research offer hope for better outcomes in the coming years," he said.